Results showed that high expression of CCNA2 was significantly associated with poor tamoxifen efficacy in ER+ breast cancer within GSE47561, Gyorffy et al. and GSE3494 (Fig. 1C, Fig. S2A and S2B, P = 0.003, 0.028 and 0.01, respectively). Here, CCNA2 is linked to breast cancer.